Article Text

Download PDFPDF
Adult nursing
Shorter intervals and sequential administration of adjuvant chemotherapy are effective in reducing the 10-year risk of recurrence and death in early breast cancer women without detrimental effects
  1. Gianluca Catania
  1. Dipartimento di Scienze della Salute, Universita degli Studi di Genova, Genova, Italy
  1. Correspondence to Dr Gianluca Catania, Universita degli Studi di Genova Dipartimento di Scienze della Salute, Genova 16132, Italy; gianluca.catania{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on: Early Breast Cancer Trialists’ Collaborative Group. Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. Lancet 2019;393:1440–52. doi:10.1016/S0140-6736(18)33137-4. Epub 8 February 2019.

Implications for practice and research

  • Oncology nurses are in the key role to put in practice a proactive approach to determine successful completion of dose-intense regimens.

  • This meta-analysis provides support for nursing research on the effect of nursing interventions delivered to women receiving a dose-intense regimen (eg, symptoms and quality of life).


Researchers have demonstrated that anthracycline and taxane regimen reduce mortality by a third compared with no chemotherapy in early breast cancer, independently of tumour characteristics.1 A previous report suggested that dose-intensification strategies including chemotherapy administration every 2 weeks or giving higher dose of drugs sequentially rather than lower dose concurrently …

View Full Text


  • Twitter @gianlucacatania

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Provenance and peer review Commissioned; internally peer reviewed.